Exploring Structure Activity Relationship of FOSL1/cJUN Inhibitors Towards Therapeutic Development for Head and Neck Squamous Cell Carcinoma

Summarise with VIRAT
Authors: Sarita Pandit
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Head and neck squamous cell carcinoma (HNSCC) remains a global health challenge, particularly in HPV-negative, advanced-stage cases where metastatic spread to distant organs results in poor overall survival. Current conventional therapies, such as cisplatin and radiation, often fail due to cancer stem cells (CSCs)—a subpopulation of cells that drive tumor recurrence, metastasis, and intrinsic chemoresistance. This presentation identifies FOSL1, a master regulator of cell proliferation and invasion, as a critical therapeutic target because it is upregulated in HNSCC CSCs and correlates with reduced patient survival. The researcher utilized a deconstruction-reconstruction-elaboration approach starting with T5224, a molecule originally developed for Phase II clinical trials in rheumatoid arthritis. By systematically breaking down and rebuilding the chemical scaffold, the study identified a specific pharmacophore, the benzoisoxazole group, essential for binding to the FOSL1 protein. Key Research Findings: Enhanced Potency: The lead analog, Compound 3, demonstrated a tenfold increase in potency over the parent compound (T5224) and significantly reduced FOSL1 protein expression in a concentration-dependent manner. Selectivity: Compound 3 showed high selectivity for cancer cells (SCC1) over normal cell lines (SGF). Anti-Metastatic Properties: In vitro scratch assays confirmed that the compound significantly inhibited cell migration and gap closure more effectively than the parent molecule. Targeting Stemness: Sphere-formation assays revealed that Compound 3 effectively inhibits the self-renewal capacity of CSCs, thereby addressing the primary cause of tumor recurrence. In Vivo Efficacy: Mouse xenograft models showed a significant reduction in tumor volume at half the T5224 dose, with no observed systemic toxicity or change in body weight.

Fields of Study & Subjects

Cancer Cells and Metastasis Computational Drug Discovery Methods Heterocyclic Compound Synthesis and Bioactivity

Publication details

Journal / source
VCU Scholars Compass (Virginia Commonwealth University)
Publication date
1 January 2026
Language
EN